Compare Stocks: AEZS, COCP, PSTV, and CALC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$3.08 +1.3%	$3.24	$3.96 ▼ $12.00	$5.52M	1.55	7,305 shs	3,223 shs
CALC CalciMedica	$0.46 -1.2%	$0.75	$0.44 ▼ $7.20	$16.05M	0.91	394,145 shs	675,809 shs
COCP Cocrystal Pharma	$1.10 -3.5%	$1.02	$0.76 ▼ $2.67	$21.96M	1.43	87,914 shs	28,740 shs
PSTV Plus Therapeutics	$3.10 +2.6%	$3.77	$2.90 ▼ $23.42	$21.34M	1.4	116,506 shs	69,368 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	0.00%	0.00%	0.00%	0.00%	+2.67%
CALC CalciMedica	-1.19%	-18.92%	-37.48%	-43.16%	-83.99%
COCP Cocrystal Pharma	-3.51%	-4.35%	+26.39%	-1.79%	-29.03%
PSTV Plus Therapeutics	+2.65%	+3.33%	-14.60%	-46.74%	-74.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$3.08 +1.3%	$3.24	$3.96 ▼ $12.00	$5.52M	1.55	7,305 shs	3,223 shs
CALC CalciMedica	$0.46 -1.2%	$0.75	$0.44 ▼ $7.20	$16.05M	0.91	394,145 shs	675,809 shs
COCP Cocrystal Pharma	$1.10 -3.5%	$1.02	$0.76 ▼ $2.67	$21.96M	1.43	87,914 shs	28,740 shs
PSTV Plus Therapeutics	$3.10 +2.6%	$3.77	$2.90 ▼ $23.42	$21.34M	1.4	116,506 shs	69,368 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	0.00%	0.00%	0.00%	0.00%	+2.67%
CALC CalciMedica	-1.19%	-18.92%	-37.48%	-43.16%	-83.99%
COCP Cocrystal Pharma	-3.51%	-4.35%	+26.39%	-1.79%	-29.03%
PSTV Plus Therapeutics	+2.65%	+3.33%	-14.60%	-46.74%	-74.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEZS Aeterna Zentaris	0.00	N/A	N/A	N/A
CALC CalciMedica	2.20	Hold	$10.00	2,053.32% Upside
COCP Cocrystal Pharma	1.00	Sell	N/A	N/A
PSTV Plus Therapeutics	2.33	Hold	$51.75	1,569.35% Upside

Current Analyst Ratings Breakdown

Latest AEZS, COCP, PSTV, and CALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/17/2026	PSTV Plus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/8/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/8/2026	PSTV Plus Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$65.00 ➝ $57.00

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEZS Aeterna Zentaris	$2.37M	2.33	N/A	N/A	$14.99 per share	0.21
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.16 per share	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.05 per share	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEZS Aeterna Zentaris	-$16.55M	-$14.86	N/A	N/A	N/A	-760.32%	-83.45%	-45.76%	N/A
CALC CalciMedica	-$29.56M	-$1.36	N/A	N/A	N/A	N/A	-863.40%	-155.24%	11/11/2026 (Estimated)
COCP Cocrystal Pharma	-$8.83M	-$0.76	N/A	N/A	N/A	N/A	-207.47%	-123.33%	11/13/2026 (Estimated)
PSTV Plus Therapeutics	-$22.39M	-$2.30	N/A	N/A	N/A	-230.24%	-198.48%	-73.13%	N/A

Latest AEZS, COCP, PSTV, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	COCP Cocrystal Pharma	-$0.17	-$0.23	-$0.06	-$0.23	$0.11 million	$0.11 million
8/13/2026	Q2 2026	PSTV Plus Therapeutics	-$0.88	-$1.31	-$0.43	-$1.31	$1.11 million	$0.41 million
8/11/2026	Q2 2026	CALC CalciMedica	-$0.2850	-$0.45	-$0.1650	-$0.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEZS Aeterna Zentaris	N/A	5.94	5.93
CALC CalciMedica	1.67	5.58	5.58
COCP Cocrystal Pharma	N/A	1.24	1.24
PSTV Plus Therapeutics	N/A	2.27	2.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEZS Aeterna Zentaris	0.73%
CALC CalciMedica	N/A
COCP Cocrystal Pharma	6.72%
PSTV Plus Therapeutics	3.28%

Insider Ownership

Company	Insider Ownership
AEZS Aeterna Zentaris	0.10%
CALC CalciMedica	28.25%
COCP Cocrystal Pharma	39.40%
PSTV Plus Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEZS Aeterna Zentaris	20	1.79 million	1.79 million	No Data
CALC CalciMedica	30	34.14 million	24.50 million	No Data
COCP Cocrystal Pharma	10	19.26 million	11.67 million	Not Optionable
PSTV Plus Therapeutics	20	6.88 million	6.71 million	Not Optionable

AEZS, COCP, PSTV, and CALC Headlines

Recent News About These Companies

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

August 20, 2026 | globenewswire.com

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

August 14, 2026 | globenewswire.com

Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives

August 13, 2026 | globenewswire.com

Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company

July 31, 2026 | finanznachrichten.de

Cerenome Launches as an Integrated CNS Oncology Company

July 31, 2026 | globenewswire.com

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

July 28, 2026 | globenewswire.com

Plus Therapeutics Inc.: Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer

July 21, 2026 | finanznachrichten.de

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

July 21, 2026 | globenewswire.com

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

July 16, 2026 | globenewswire.com

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

July 14, 2026 | globenewswire.com

Plus Therapeutics Inc.

July 2, 2026 | barrons.com

Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)

June 30, 2026 | finance.yahoo.com

Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript

June 30, 2026 | seekingalpha.com

Plus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial Progress

June 30, 2026 | quiverquant.comQ

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

June 30, 2026 | globenewswire.com

Plus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration Assay

June 25, 2026 | quiverquant.comQ

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

June 25, 2026 | globenewswire.com

Plus Therapeutics to Provide Business Update Call on June 30, 2026

June 23, 2026 | globenewswire.com

Plus Therapeutics Launches New At-The-Market Equity Program

June 5, 2026 | tipranks.com

Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform

June 4, 2026 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEZS, COCP, PSTV, and CALC Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

CalciMedica NASDAQ:CALC

$0.46 -0.01 (-1.19%)

As of 08/28/2026 04:00 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Cocrystal Pharma NASDAQ:COCP

$1.10 -0.04 (-3.51%)

As of 08/28/2026 04:00 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Plus Therapeutics NASDAQ:PSTV

$3.10 +0.08 (+2.65%)

As of 08/27/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AEZS, COCP, PSTV, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AEZS, COCP, PSTV, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AEZS, COCP, PSTV, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEZS, COCP, PSTV, and CALC Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

CalciMedica NASDAQ:CALC

Cocrystal Pharma NASDAQ:COCP

Plus Therapeutics NASDAQ:PSTV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AEZS, COCP, PSTV, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AEZS, COCP, PSTV, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AEZS, COCP, PSTV, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEZS, COCP, PSTV, and CALC Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

CalciMedica NASDAQ:CALC

Cocrystal Pharma NASDAQ:COCP

Plus Therapeutics NASDAQ:PSTV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools